Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference
Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), will participate in the Citizens Life Sciences Conference. The company's management will engage in a fireside chat on May 7, 2025, at 1:00 p.m. ET. Investors can access the live and archived webcast through Clearside's website under the Investors section: Events and Presentations. The webcast recording will remain available for three months after the event.
Clearside Biomedical (NASDAQ: CLSD), un'azienda biofarmaceutica specializzata nello sviluppo di terapie per la parte posteriore dell'occhio tramite lo spazio suprachoroidale (SCS®), parteciperà alla Citizens Life Sciences Conference. Il management dell'azienda prenderà parte a una conversazione informale il 7 maggio 2025, alle 13:00 ET. Gli investitori potranno seguire la diretta e rivedere la registrazione sul sito web di Clearside, nella sezione Investitori: Eventi e Presentazioni. La registrazione sarà disponibile per tre mesi dopo l'evento.
Clearside Biomedical (NASDAQ: CLSD), una compañía biofarmacéutica centrada en ofrecer terapias para la parte posterior del ojo a través del espacio supracoroideo (SCS®), participará en la Citizens Life Sciences Conference. La dirección de la empresa participará en una charla informal el 7 de mayo de 2025 a la 1:00 p.m. ET. Los inversores podrán acceder a la transmisión en vivo y a la grabación a través del sitio web de Clearside, en la sección de Inversores: Eventos y Presentaciones. La grabación estará disponible durante tres meses después del evento.
Clearside Biomedical (NASDAQ: CLSD)는 suprachoroidal space(SCS®)를 통해 눈 뒤쪽에 치료제를 전달하는 데 주력하는 생명공학 회사로, Citizens Life Sciences Conference에 참가할 예정입니다. 회사 경영진은 2025년 5월 7일 오후 1시(동부시간)에 진행되는 대담에 참여합니다. 투자자들은 Clearside 웹사이트 내 투자자 섹션의 이벤트 및 프레젠테이션에서 생중계 및 녹화방송을 시청할 수 있습니다. 녹화방송은 행사 후 3개월간 제공됩니다.
Clearside Biomedical (NASDAQ : CLSD), une société biopharmaceutique spécialisée dans la fourniture de thérapies pour la partie postérieure de l'œil via l'espace suprachoroïdien (SCS®), participera à la Citizens Life Sciences Conference. La direction de l'entreprise prendra part à une discussion informelle le 7 mai 2025 à 13h00 ET. Les investisseurs pourront accéder au webinaire en direct et à son enregistrement via le site web de Clearside, dans la section Investisseurs : Événements et Présentations. L'enregistrement restera disponible pendant trois mois après l'événement.
Clearside Biomedical (NASDAQ: CLSD), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapien für den hinteren Augenbereich über den suprachoroidalen Raum (SCS®) spezialisiert hat, wird an der Citizens Life Sciences Conference teilnehmen. Das Management des Unternehmens wird am 7. Mai 2025 um 13:00 Uhr ET an einem Gespräch am Kamin teilnehmen. Investoren können den Live-Stream und die Aufzeichnung über die Website von Clearside im Bereich Investoren: Veranstaltungen und Präsentationen abrufen. Die Aufzeichnung ist drei Monate nach der Veranstaltung verfügbar.
- None.
- None.
ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025, at 1:00 p.m. ET.
A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
Source: Clearside Biomedical, Inc.
FAQ
When is Clearside Biomedical (CLSD) presenting at the Citizens Life Sciences Conference?
How can investors access Clearside Biomedical's (CLSD) presentation at the Citizens Life Sciences Conference?
How long will Clearside Biomedical's (CLSD) conference presentation webcast be available?
What is Clearside Biomedical's (CLSD) main focus as a company?
